Cytokinetics Q4 Revenue Rises 5% to $17.7M, Plans Q2 EU Myqorzo Launch
Cytokinetics reported a Q4 net loss of $1.50 per share, up from $1.26 a year earlier due to higher R&D and G&A costs, while revenues rose 5% to $17.7 million, beating forecasts. It holds $1.22 billion cash and plans a Q2 EU launch of Myqorzo.
1. Q4 Results
Cytokinetics reported a fourth-quarter net loss of $1.50 per share compared with $1.26 in the year-ago period. Revenues reached $17.7 million, up 5% year over year, while R&D expenses grew 11.5% to $104.4 million and general and administrative costs rose 47.2% to $91.7 million.
2. Cash Position
As of December 31, cash, equivalents and investments totaled $1.22 billion, including $100 million from the latest tranche of the Royalty Pharma loan facility. This strong balance sheet underpins both the upcoming commercialization of Myqorzo and ongoing clinical programs.
3. Myqorzo Launch and Regulatory Updates
Myqorzo (aficamten) received FDA approval in December 2025 for obstructive HCM and has secured EU and Chinese authorizations. The first European launch is scheduled in Germany in Q2 2026, and a supplemental NDA for label expansion has been submitted with a decision expected in Q4 2026.
4. Pipeline and Catalysts
Key Phase III trials include ACACIA-HCM and MAPLE-HCM, with topline data due in Q2 2026. Additional studies—COMET-HF for heart failure and AMBER-HFpEF for preserved ejection fraction—are enrolling through 2026, offering near-term clinical readouts.